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For early melanoma, surgical excision is the treatment of choice and this strategy is initially 
curative for the majority of patients. However, only approximately 40-60% of patients who have 
surgery alone and higher risk stages, will be disease-free after 5 years of follow up, depending on 
the original III stage of the disease. These patients will relapse either with locoregional or 
disseminated disease. Adjuvant therapies are required to be able to reduce the recurrence rate on 
radically operated patients in these different initial stages of the disease. 
New treatments have appeared in the landscape of metastatic melanoma and this have opened to 
new potential scenarios in the adjuvant setting. In particular immunotherapy, immunocheckpoint 
inhibitors and target therapies have been recently published their potential advantage from the 
results obtained in the curative setting for stage IV, where the different mechanisms of action 
could even be potentially more active and more responsive due to the limited subclinical 
presence of disease in the patients after surgical complete resection.  
Currently, interferon alfa (IFN), ipilimumab and more recently antipd1  are immunotherapeutic 
options  are approved for adjuvant treatment of melanoma in US, while in EU only IFN is for 
clinical use. Other adjuvant treatments have been published and are currently in the phase of 
approval trough FDA and EMA, based on the results of clinical trials that include PD-1 
inhibitors and small-molecule BRAF+ MEK inhibitors. 
Actually the first study designed to answer this question is the Keynote 054 (pembrolizumab 
(MK-3475) versus Placebo after complete  resection of high stage III Melanoma) which, through 
a cross over plan on recurring patients, will be able to define if patients treated in the adjuvant 
setting will describe a better survival compared to patients treated after recurrence. 
A completely new scenario will also become evident from the opportunity to open the 
therapeutic approach from a neoadjuvant setting: since new therapies are available, patients  with 
macroscopic nodal metastases so far considered operable, might be sent to a medical approach in 
stage III and surgery proposed only as final resource both to remove disease residuals and to 
confirm the efficacy of the treatment, while in advanced stage III/IV not operable at the 
diagnosis of an initially disease advanced situation, patients may partially respond to the new 
therapies and after obtaining a partial/complete reduction of the disease, become virtually 
operable from the surgical point of view. 
 
1.Introduction 
Melanoma accounts for a small percentage of all skin malignancies, but it is responsible for the 
majority of deaths due to skin cancers worldwide1. Moreover, cause of the increasing aging of 
the population, the age at death of melanoma patients has steadily increased, with present 
predictions showing that the number of melanoma cases will increase. Due to the introduction of 
new systemic drugs, we assist to an increase survival for advanced, unresectable and metastatic 
melanoma over the last few years. This unprecedented development is related to the introduction 
of immune checkpoint inhibitors with antibodies against CTLA-4 and PD-1 and targeted therapy 
with BRAF and MEK inhibitors. 
 The recent developments and approvals in immunotherapy and targeted agents that have 
significantly changed the landscape of melanoma therapy in the metastatic setting can represent a 
great promise for adjuvant and neoadjuvant treatment in high-risk or advanced locoregional 
disease. 
All adjuvant approaches had to be initially tested on an advanced disease therapeutic approach. 
This review of historical and recent drugs is willing to report on the situation we are facing at the 
moment where we stand in front of a new era in the therapeutical approach of advanced 
melanoma patients which is the basis of novel approaches in the adjuvant settings as recent 
studies come to publication and start their approval pathways through regulatory agencies 
Worldwide. In this review for an easier comparison between old and recent studies we will 







Melanoma patients with intermediate and thick tumours are offered a sentinel node biopsy 
(SLNB) to identify lymph node spread as this procedure has prognostic value, stratifying patients 
in different risk categories5. Other parameters such as mitoses and ulceration are also helpful in 
thinner melanomas6. After a positive SLN, the current guidelines recommended a complete 
lymph node dissection (CLND) of all the involved metastatic basins but in selected patients (to 
be defined if with very small deposits in the lymph node, as for breast cancer patients or with 
macroscopic disease due to a virtual situation of microscopic subclinical advanced disease7) may 
be given the choice of avoiding a lymphadenectomy. The final results of the DecoG and MSLT 
II trials8,9 may be useful to propose new  biologically driven guide lines on N+ patients, but a 
careful discussion will be needed once all data are supported by longer follow up periods: so far 
the published data on these 2 trials do not show any survival benefit for the patients undergoing a 
CLND  after the diagnosis of metastatic SLN, but only a reduced risk of nodal locoregional 
relapse for the patients immediately operated. On the contrary if the subgroups analysis on 
MSLT II study is brought to a speculative discussion, the opposite seems to be more rational: 
patients with microscopic deposits in the SLN could benefit from a CLND, while patients with 
macrometastases would reach the same OS whether operated or not with an immediate CLND. 
The biological explanation of this different behaviour can be related to the fact that a certain 
percentage of patients with micrometastases could only have few tumoral cells into the nodes 
that are removed with a CLND, while in case of macrometastases, the disease may have also 
spread heamatogenously, making totally un-useful the proposed CLND.  
 
 
The number of positive lymph nodes (LN) and its ratio represent the two most important 
prognostic factors in stage III melanoma patients10,11. The 5-year survival of melanoma patients 
with LN metastasis ranges from an average of 20-40% when patients present with clinically 
evident nodal disease, improving to 67% when patients had their LN metastasis identified with 
SLNB. Patients who have CLND after a positive SLNB show a wide heterogeneity in their 
prognosis, with 5-year survival rates ranging from 15% in case of multiple positive LNs to 90% 
in case of a small cellular metastatic deposits in the SLN where the prognosis is even more 
favorable then that of high risk stage II patients (>4 mm Breslow, ulcerated primary melanoma 
pts.).  
 
The risk of recurrence in stage III patients is very wide, and no available biomarker for 
predicting recurrence have been established so far. The best predictor of recurrence is the 
number of LN involved. Different nomograms based on clinical pathological features have been 
proposed for predicting which patients with positive SLN are more at risk of relapse12. 
 
 
3. BIOCHEMOTHERAPY  
Cisplatin and interleukin-2 (IL-2)–based biochemotherapy have been used for  stage III 
melanoma. The trial on 432 high-risk patients assigned to either three cycles of cisplatin, 
vinblastine, dacarbazine, IL-2, and IFN-α given over a 9-week period or to high-dose IFN-α for 1 
year. Results showed that the biochemotherapy regimen significantly prolonged RFS at a median 
follow-up of 7.2 years 13. However, there was no significant difference in the OS (5-year rate 
56% for both treatment arms; HR 0.98; 95% CI, 0.74–1.31). The biochemotherapy regimen was 
substantially more toxic, with grade 3 or 4 side effects (consisting primarily of hematologic and 
gastrointestinal toxicity) observed in 76% of participants. Neurologic, psychiatric, and hepatic 
toxicities were the most frequent with high-dose IFN-α. Biochemotherapy toxicities were limited 
to the 9-week treatment period, while IFN-α toxicities were distributed across the year of 
treatment. Even though the biochemotherapy regimen was the first to produce a significant 
improvement in RFS compared with an active control arm, the lack of OS benefit coupled with 
the failure of this regimen to show an OS benefit relative to chemotherapy alone in patients with 




4.Adjuvant CT with/without BCG/INF 
 
 
Hypothetically, non-detected melanoma micrometastases might be the cause of future relapses 
and/or may induce tumor tolerance in the host. Different clinical trials comparing  patients 
treated after CLND with immunotherapy with interferon-alpha-2b (IFN-α-2b),  bacille 
Calmette–Guérin vaccine,  dacarbazine, or a combination of the last two failed iun showing a 
higher survival ratein the treatment arm. 151617 
 
A regimen of IFN-α-2b administered for 1 year at maximum tolerated doses was approved by the 
FDA in 1995 and later on by EMA for the adjuvant therapy of patients with high-risk (AJCC 
Stage IIB and III) melanoma: up to now this is still the only approved drug in Europe for 
melanoma patients in the adjuvant setting.  
Adjuvant IFN-α therapies, which could induce TH1 anti-tumor responses, are based on these 
hypotheses and might be of benefit to some patients with possible micrometastases 18. 
IFN-α directly inhibits the proliferation of melanoma cells. Moreover, IFN-α decreases 
intracellular and secretory levels of VEGF in melanoma cell lines 19, thus reducing microvessel 
density around the tumour. It has been described  to be able to promot tumor immunogenicity 
and enhances anti-tumor immunity. MHC class I Expression has been analysed by several 
studies  on both melanoma and immune cells when stimulated with IFN-α20. The use of IFN-α as 
an adjuvant therapy in melanoma patients is based on the hypothesis that micrometastatic disease 
is the cause of future relapses and may induce tumor tolerance in the host. Unfortunately the 
global efficacy on overall survival is as low as 3%.  
During more then 3 decades, low- (LDI), intermediate (IDI)- and high-dose (HDI) IFN-α 
regimens have been tested in randomized trials in the adjuvant setting21,22; these studies greatly 
differed also in terms of the therapy duration, route of administration and the type of IFNs used.   
As just mentioned, the most important discussion is clearly on the dosage: a significant impact 
on overall survival (OS) was only shown with the high-dose IFN-α2b intravenous regimen (HDI) 
when compared to observation only (US Intergroup trials E1684: median OS 3.82 vs 2.78 years, 
p=0.0237) and the GMK vaccine (E1694: OS HR=1.52; P= 0.009).. The outcomes of the E1684 
trial in 1995 led to the regulatory approval of IFN by the US Food and Drug Administration 
(FDA). However, these results were not confirmed in the following E1690 trial that compared 
HDI versus LDI versus control. In fact it failed in demonstrating a significant benefit of the HDI, 
but bearing more adverse events 23. Furthermore, different randomized trials reported other 
conflicting results, never offering the real hint to the therapeutic benefit of IFN. The randomized 
phase III DeCOG trial compared LDI vs LDI plus dacarbazine vs observation in stage III 
melanoma patients. The Authors found a DFS and OS for the LDI regimen, and, interestingly, a 
worse therapeutic effect when dacarbazine was added 24.  
The EORTC 18952 adjuvant IFN trial  was designed to investigate also if an antiangiogenic 
effect could be relevant in the potential benefit of adjuvant  IFN25. In this trial researchers 
compared: I) a 4 weeks-induction phase using IFN at 10 million IU/m2/d for 5 days/week for 4 
weeks, followed by a maintenance phase with 10 million IU three times a week for 12 months; 
II) 5 million IU 3 days/week for 24 months; III) observation alone. After the long median follow-
up of 11 years, the only difference reported was the distant metastasis-free interval with an HR 
of 0.95 for the shorter maintenance group versus HR of 0.82 for the longer maintenance group 
(p=0.027).  
A metanalysis found that IFNα slightly improved DFS (risk reduction=18%) and OS (risk 
reduction=11%) in high-risk cutaneous melanoma patients, however, the different studies 
analysed did not show any differences between low and high dosages26. Wheatley et al. reported 
a 5-year absolute benefit of about 3%, with greater efficacy in patients where the primary tumor 
was ulcerated27 .  
Clinical trials comparing adjuvant HDI to ipilimumab (NCT01274338, NCT01708941, 
NCT02506153) or to pembrolizumab (NCT02506153) are ongoing, and the results are still 
pending. 
Pegylated IFNα (peg-IFN), which should have a longer half-life through IFN’s covalent binding 
to polyethylene glycol, was tested in the European Organization for Research and Treatment of 
Cancer (EORTC) trial 1899128. The trial tested an induction dosage of subcutaneous peg-IFN at 
6 μg/kg/week for 8 weeks, followed by a maintenance dose of weekly subcutaneous injections at 
3 μg/kg for up to 5 years. A rather slight improvement of the relapse free survival for the peg-
IFN was reported (7-year RFS rate: 39.1% versus 34.6%) but authors did not find any 
differences in OS and distant metastasis-free survival between the treatment and the sole 
observation group. A pooled analysis of the EORTC trials 18952 and 18991 found that the 
primary tumor ulceration and the presence of only micrometastases as lymph nodal involvement, 
could be predictive of IFN efficacy29. Moreover, one study reported peg-IFN’s association with 
higher rates of grade 3-4 Adverse Events (47.3% versus 25.2%; p<0.0001) and treatment 
discontinuations (54.3% versus 30.4%) compared to IFNα30. 
 
6.VACCINE FOR ADJUVANT TREATMENT 
Dendritic cells (DC) are the most efficient antigen-presenting cells of the immune system due to 
their capacity to activate and prime naive T cells31.   They play a fundamental role in anticancer 
immunotherapy  due to their role in  induction of antitumor immunity. DC can be generated ex 
vivo, activated, and loaded with tumor antigens before to be injected into the patients.32 The 
rationale to include DC vaccination in the  adjuvant treatment in stage III patients is that high 
tumor load causes immune suppression by secretion of immunosuppressive cytokines, and 
attraction of regulatory T cells and myeloid derived suppressor cells in the tumor 
microenvironment. The clinical effectiveness of DC vaccination might be improved by 
increasing the number of antigens. The melanoma differentiation antigens gp100 and tyrosinase 
were previously  selected due to their expression on melanoma cells and have shown to be 
capable of inducing functional cytotoxic T cells.33 However, recent findings show that tumor-
specific mutations, leading to neoantigens, may drive potent antitumor responses34.  Carreno and 
colleagues found that a DC vaccine with carefully selected patient-specific neoantigens, led to an 
increase in the breadth and diversity of melanoma neoantigen-specific T cells in peripheral blood 
samples of three stage IV melanoma patients35.  As most mutated proteins are essentially unique 
to a tumor, personalized antigen selection might be beneficial in vaccination strategies.  A great 
challenge will be the identification of the right immunogenic neoantigens, especially in stage III 
melanoma patients, since only a minimal amount of tumor material might be available36. For this 
reason, and in light of tumor heterogeneity, it might be preferable to combine commonly 
expressed melanoma differentiation antigens with patient-specific neoantigens in future DC 
vaccines. 
 
7.Adjuvant vaccine with melanoma antigen GM-2 ganglioside 
  
The GM2 ganglioside is an antigen expressed in the majority of melanomas. The GM2-KLH/QS-
21 vaccine induces high immunoglobulin M (IgM) and IgG antibody responses documented in 
early phase clinical trials at the EORTC melanoma group37. The EORTC 18961 trial compared 
the efficacy of GM2-KLH/QS-21 vaccination versus observation on high risk primary melanoma 
(with negative SLN). A total of 1,314 patients with a primary tumor > 1.50 mm in thickness 
were randomly assigned to GM2-KLH/QS-21 vaccination (n = 657) or observation (n = 657). 
Treatment consisted of subcutaneous injections once per week from week 1 to 4, then every 3 
months for the first 2 years and every 6 months during the third year. Relapse-free survival 
(RFS) was the primary endpoint. Secondary endpoints were distant metastasis-free survival 
(DMFS) and OS. After a median follow-up of 1.8 years, the trial was stopped at the second 
interim analysis for futility regarding RFS (hazard ratio [HR], 1.00; P = .99) and detrimental 
outcome regarding OS (HR, 1.66; P = .02). After a median follow-up of 4.2 years, 400 relapses, 
nine deaths without relapse and a total of 236 deaths had been recorded. At 4 years, the 
vaccination arm showed a decreased RFS rate of 1.2% (HR, 1.03; 95% CI, 0.84 to 1.25) and OS 
rate of 2.1% (HR, 1.16; 95% CI, 0.90 to 1.51). GM2-KLH/QS-21 vaccination does not improve 
outcome for patients with stage II melanoma and may induce immune tolerance to tumoral 







MAGE-A3 is expressed on approximately 60% of melanoma specimens as a tumour specific 
protein. The DERMA (ADjuvant ImmunothERapy with MAGE3 in MelanomA) is  a double-
blind, randomized, placebo-controlled phase III study of recombinant MAGE-A3 with AS15 
antigen-specific cancer immunotherapeutic (ASCI) in stage IIIB/C patients with MAGE-A3–
positive. The study was based on an EORTC phase II study of patients with stage IV M1A 
disease that identified a superior survival benefit for patients receiving the MAGE-A3 vaccine 
treated with the AS15 rather than the ASO2B adjuvant (HR 0.55; 95% CI, 0.28–1.06) 38. 
Furthermore, a genetic predictor identified a group of patients receiving MAGE-A3 with AS15 
ASCI with a better OS (HR 0.27; 95% CI, 0.08–0.89). The DERMA study screened 3,914 
patients and randomly assigned 1,344 patients 2:1 to 13 intramuscular injections of vaccine or 
placebo. The latter  failed to meet its coprimary endpoint of DFS in either the overall population 
of patients studied or in those with the potential predictive gene signature. 
 To further investigate the role of the Gene Signature (GS) in predicting a response to MAGE-A3 
immunotherapeutic the PREDICT study was conducted in 49 centers in Europe and the United 
States on advanced melanoma patients. Because of frequent rapid progression in M1b-c 
melanoma, patients naive to previous systemic treatment with non-resectable stage IIIB-C and 
IV-M1a melanoma were included. This phase II study was not controlled, as placebo 
administration is unethical in this population and no highly effective treatment was available at 
the time of study design.  
The OS of MAGE-A3-positive patients with unresectable stage IIIB-C/IV-M1a demonstrated an 
overall 1-year OS rate of 83.5%. 1-year OS rates did not change when stratified in GS− and GS+ 
patients, indicating that in this study, GS was not predictive of outcome. Unexpectedly, the 
objective response rate was lower in this study than in other studies carried out in the same 
setting with the MAGE-A3 immunotherapeutic.  
The MAGE 3 vaccine will probably no more undergo clinical investigations in the future, both in 
the adjuvant or therapeutic settings. 
 
9.BEVACIZUMAB 
Since Bevacizumab has reported to have some activity in patients with advanced melanoma, it 
has been valuated in the adjuvant setting. In a phase III multicenter trial conducted in the United 
Kingdom, 1,343 patients with resected stage IIB, IIC, or III disease were randomly assigned to 
receive 1 year of bevacizumab treatment (7.5 mg/kg every 3 weeks) or to observation. 39 Results 
showed no significant difference in OS at a median follow-up of 25 months,  (HR 0.97; 95% CI, 
0.78–1.22; p = .76). However, there was a significant increase in the DFS (1-year and 2-year 
disease-free rates 77% vs. 70% and 59% vs. 57%, respectively; HR 0.83; 95% CI, 0.70–0.98). 
Interpretation of the trial and the potential role of bevacizumab will require further follow-up to 
assess the 5-year OS rate. Until then, the use of bevacizumab in the adjuvant setting for patients 
with advanced melanoma is not recommended. 
 
 
10.RADIATION THERAPY AS ADJUVANT TREATMENT 
Adjuvant radiation treatment following CLND in the melanoma patient population has been 
suggested and investigated in order to gain regional control and consequently to improve 
survival40.  Disease-free, survival rates and complications drive important issues on the 
therapeutic post CLND discussions. Historically, melanoma has been thought to be a relatively 
radioresistant tumour. Nowadays, radiation delivered according to the hypofractionated schedule 
is the most used, although there are no data to confirm that this schedule improves the 
therapeutic impact. Almost all the reviewed studies were retrospective, which could have led to 
an underestimation of the true incidence of the treatment toxicity and morbidity. Improved Loco 
regional control, but not  OS has been reported when performing adjuvant radiotherapy after 
CLND for metastases of melanoma41. A recent study is describing an improvement in a subgroup 
of patients with a particular gene expression signature who would probably benefit from 
adjuvant radiotherapy42. The available data indicate the need for improved regional control rates 
in patients with extranodal extension, multiple involved nodes (more than three) and patients 
with large involved nodes (larger than 3 cm)43. The complications seem manageable and consist 
mainly of fibrosis and edema. This treatment is mentioned in most guide lines where a discussion 
case by case is suggested after CLND. 
 
11.TRIAL IN RESECTED STAGE II 
 
12.NEW DRUGS IN STAGE III 
 
It is well known that T-cell responses are regulated through a complex balance of inhibitory and 
activating signals and that the tumour itself can dysregulate these pathways, leading therefore to 
an impairment of the immune system activities. The relevant new concept that was developed 
following the failure of cytokine-based immunotherapy and the increasing evidence of the 
clinical activity of different target therapies in several cancer types  was constituted by the 
potential of targeting these inhibitory and activating immunological synapses as a new tool to 
promote the immune response44. Until now, two main types of immune modulating drug 
antibodies have been developed and used in the treatment of advanced metastatic melanoma, the 




12.1IPILIMUMAB IN STAGE III 
 
The  European Organisation for Research and Treatment of Cancer (EORTC) concluded the 
18071 study on adjuvant ipilimumab versus placebo after complete resection of high-risk stage 
III melanoma patients45. It is the first trial with an immune checkpoint inhibitor used 
postoperatively after lymph node dissection, showing significant improvement in recurrence-free 
survival and overall survival (5-year RFS rates 40.8% vs. 30.3% and 5-year OS rates 65.4% vs. 
54.4%, respectively). 
Despite clear benefits in reduction of risk of death, the use of adjuvant ipilimumab has not 
reached a global use: only FDA has approved the drug, while EMA did not activate the 
discussion on the same clinical indication. Considering the significant adverse event rates  (grade 
3–4 immune-related adverse events occurred in 41.6% of patients treated with ipilimumab as 
compared to 2.7% in placebo arm), resulting in only 42% of patients receiving more than four 
doses of ipilimumab, the survival benefit of ipilimumab over placebo was generally consistent 
across subgroups. This benefit was observed not only in patients with microscopic involvement 
in the SLN but also in patients with macroscopic or palpable nodes. Similarly, in contrast to 
interferon alfa, for which ulceration is the overriding determinant of activity, ipilimumab 
prolonged survival among patients with nonulcerated melanoma and among those with ulcerated 
melanoma and with no difference in terms of metastatic nodal involvement. The main topic for 
discussion has to be the dosage for IPI adjuvant administration: the EORTC study was designed 
to propose the same dosage of 10 mg/m2 for 3 years following the very first findings and study 
results in advanced melanoma46, but later the dosage of 3 mg/m2 was defined as efficacy as the 
higher dosage in this more advanced melanoma patients setting, so it appears irrational to 
approve for adjuvant use a drug that should be used at a more toxic, prolonged and expensive 
schedule than the same for an advanced disease indication.  
In conclusion, it should be acknowledged that considering the low number of patients  who had 
received the induction and mantainance phase of ipilimumab in the trial, the severe toxicity in a 
large number of patients, plus the lack of difference in DFS between the two dosage (3mg/kg and 
the 10 mg/kg) reported in the ASCO abstract47 (cit) had raised doubts on the usage of this drug as 
potential new candidate worldwide as adjuvant therapy in melanoma. 
 
12.2ANTI PD-1 IN STAGE III 
Anti PD1 have beenapproved as first line treatmetn for metastatic melanoma.  
Nivolumab and ipilimumab value in the adjuvant setting has been evaluated in a randomized, 
double-blind, phase 3 trial, randomly assigned 906 patients (≥15 years of age) who were 
undergoing complete resection of stage IIIB, IIIC, or IV melanoma to receive an intravenous 
infusion of either nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks (453 
patients) or ipilimumab at a dose of 10 mg per kilogram every 3 weeks for four doses and then 
every 12 weeks (453 patients)48. The period of treatment was up to 1 year or until disease 
recurrence, a report of unacceptable toxic effects, or withdrawal of consent. The 12-month rate 
of RFS primary endpoint was 70.5% in the nivolumab group and 60.8% in the ipilimumab group. 
Grade 3 or 4 adverse events that investigators deemed to be related to a trial drug were reported 
in 14.4% of the patients in the nivolumab group and in 45.9% of those in the ipilimumab group. 
There were 2 deaths (0.4%) from toxic effects (marrow aplasia and colitis, both of which 
occurred more than 100 days after the last dose) in the ipilimumab group and no treatment-
related deaths in the nivolumab group. The pathway for approval is under way through the 
regulatory agencies Worldwide (a part from the USA) and they will be approved by the time this 
article will be published. 
Concerning Pembrolizumab, Keynote 054 tried to assess whether post-resection adjuvant therapy 
with pembrolizumab improves recurrence-free survival (RFS) as compared to placebo for high-
risk participants with melanoma (Stage IIIA [> 1 mm metastasis], IIIB and IIIC). Participants 
were stratified for stage of disease and region and then were randomly assigned to receive either 
pembrolizumab or placebo. 1019 stage IIIA-C melanoma patients were  enrolled in the study.49 
Patients were randomized to 200 mg of pembrolizumab (n = 514) or placebo (n = 505) 
intravenously every 3 weeks for a total of 18 doses (approximately 1year) or until disease 
recurrence or unacceptable toxicity. Regarding - BRAF status, 40.9% had a V600E or V600K 
mutation, 6.8% had another  mutation, 45.3% were wild-type, and the status was unknown for 
7.0%. The primary endpoint (RFS rate) was 71.4% in pembrolizumab arm, (CI: 95%, 66.8–75.4) 
versus 53.2% in placebo arm (CI: 95%, 47.9–58.2). An RFS benefit with the PD-1 inhibitor was 
observed across patients with either stage IIIA, IIIB, or IIIC disease. Grade 3–5 treatment-related 
adverse events occurred in 14.7% of the pembrolizumab arm versus 3.4% of the placebo group. 
The 1-year RFS rate was 77.1% in the PD-L1–positive group, (CI: 95%, 72.7–80.9) in the active 
arm and 62.6% (CI: 96%, 57.7–67.0) in the placebo one (HR, 0.54; CI: 95%, 0.42–0.69; P < 
.001). The 18-month RFS rates were 74.2% versus 54.5%, respectively. 
Among PD-L1–negative patients, the 1-year RFS rates were 72.2% (CI: 95%, 58.6–82.0) in the 
pembrolizumab arm versus 52.2% (CI:95%, 38.2–64.5) in the placebo group (HR, 0.47; CI:95%, 
0.26–0.8; P = .01). The 18-month RFS rates were 60.6% versus 52.2%, respectively [37]. 
In BRAF V600E positive patients, the 1-year RFS rate was 72.5% with pembrolizumab versus 
58.6% with placebo (HR, 0.57; CI: 99%, 0.37–0.89; P = .0009). The 18-month RFS rates were 
69.2% versus 52.4%, respectively [37]. 
On the other hand, among BRAF wild-type patients, the 1-year RFS rate was 73.0% with 
pembrolizumab versus 59.7% with placebo (HR, 0.64; CI: 99%, 0.42–0.96; P = .0039). The 18-
month RFS rates were 66.7% versus 48.8%, respectively. 
 
The SWOG S1404 is a Phase III trial comparing high-dose IFNα with pembrolizumab (at doses 
of 200 mg) in patients with high-risk resected melanoma (stages III A-C and IV with no evidence 
of disease) for 52 weeks 50. Primary outcomes include OS and  RFS (ClinicalTrials.gov number: 




12.3 BRAF INHIBITORS IN STAGE III 
 
Approximately 50% of melanoma tumors have an activating mutation in the BRAF oncogene, 
which results in the constitutive activation of the MAP kinase signaling pathway51. Potent 
selective antagonists of mutant BRAF (vemurafenib and dabrafenib) are regarded as standard of 
care for metastatic BRAF mutant melanoma52 53  Of at least as much clinical importance, 
however, is the fact that approximately 90% of patients whose cancers carry the BRAF mutation 
have some tumor shrinkage with targeted inhibitors and that these responses occur very rapidly. 
This rapid response rate can provide palliative relief for patients with significant tumor-related 
symptoms but usually lasts 6 to 9 months when often a fast recurring disease appears and other 
therapies need to be considered 54 55 56 57 58.  
Activated BRAF phosphorylates MEK, the next downstream target in the MAP kinase pathway. 
Trametinib and Cobimetinib are selective MEK inhibitors and both have been shown to improve 
median progression free and overall survival in comparison to chemotherapy in BRAF mutant 
melanoma6264,59  Dual inhibition of both BRAF and MEK pathways in BRAF mutant disease is 




12.4Single drug adjuvant treatment with BRAF inhibitor 
The BRIM 8 study was designed as a double bling placebo controlled study of adjuvant  
vemurafenib in patients with completed resected BRAF V600+ mutant melanoma at high risk for 
recurrence. Results from this study showed a clinical benefit of the treatment arm in stages IIC-
IIIB  (HR=0.54, p<0.001) but not for stage  IIIC (HR=0.80, p=0.26), when survival estimates 
curves are not significantly different. Considering the study design, the primary DFS endpoint 
was not met in patients with resected stage IIIC BRAFV600+ melanoma, although one year of 
adjuvant vemurafenib showed a numerical DFS benefit in patients with resected stage 
IIC/IIIA/IIIB disease.  
The role of BRAF inhibitor alone should be put in the context of recently reported trials. 
The placebo-controlled COMBI-AD study showed that combination adjuvant treatment with a 
MEK and a BRAF inhibitor is able to reduce the risk of recurrence in patients with resected stage 
III BRAFV600+ melanoma (HR 0·47, 95% CI 0·39–0·58; p<0.001) (referenza). In addition, a 
recent head-to-head adjuvant study (CheckMate 238) comparing nivolumab versus ipilimumab 
in patients with resected stage IIIB/C–IV melanoma showed that nivolumab significantly 
reduced the rate of recurrence or death (HR 0·65, 95% CI 0·51–0·83, p<0.001) with a lower 
incidence of grade 3/4 events (25·4% vs 55·2%) and AE-related discontinuation rate (9·7% vs 
42·6%)56. Based on these results, it is clear that combination adjuvant treatment with BRAF and 
MEK inhibitors or single-agent nivolumab provide more favourable DFS and survival outcomes 
in patients with melanoma who are at high risk of recurrence. Although, we cannot exclude a 
role for single-agent BRAF inhibitors within certain disease substages (IIC) of this patient 
population, although there are no ongoing or planned studies to explore this.   
 The treatment with single drug BRAF inhibitor/s side effects may be one important aspect to 
consider for not approving the treatment in the adjuvant settings: these include a variety of 
different effects with the majority occurring on the skin and appendage60,61,62. The most common 
adverse events recorded in the BRIM-3 registration trial included arthralgia, fatigue, nausea, 
rashes, photosensitivity and cutaneous squamous cell carcinoma (cSCC) or keratoacanthoma 
(KA)63. The dose was modified or interrupted due to adverse events in 38% of patients treated 
with vemurafenib and permanently discontinued in only 7% of the patients treated. When 
transferring these treatment/s from advanced melanoma patients into a concept of adjuvant 
therapy all these aspects have to be considered: globally a high percentage of patients would not 
benefit from any adjuvant therapy as already cured by surgery: a treatment with important side 
effects and an alteration of the quality of life with no selection on the patients who may really 
benefit form a treatment is not going to be easily accepted by most patients.  
 
12.5Combination target therapy 
 
The results of the  fase III COMBI-AD adjuvant study Adjuvant Dabrafenib plus Trametinib in 
Stage III BRAF-Mutated Melanoma have been positive and will certainly modify the clinical 
practice in the next future. This was a double-blind, placebo-controlled, phase 3 trial, enrolling 
870 patients with completely resected, stage III melanoma with BRAF V600E or V600K 
mutations that were randomly assigned to receive oral dabrafenib at a dose of 150 mg twice daily 
plus trametinib at a dose of 2 mg once daily (combination therapy, 438 patients) or two matched 
placebo tablets (432 patients) for 12 months. Primary  end point was the RFS and showed the 
58% in the combination-therapy group versus 39% in the placebo arm group (P<0.001). The 
main secondary end point was overall survival and formally did not reach the forecasted results 
but in any case the 3-year overall survival rate was 86% in the combination-therapy group and 
77% in the placebo group (P = 0.0006), instead of the prespecified interim analysis boundary of 
P=0.000019. The safety profile of dabrafenib plus trametinib was consistent with that observed 
with the combination in patients with metastatic melanoma. 64 The pathway for approval in the 
adjuvant setting is under way through the regulatory agencies Worldwide and might be approved 
by the time this article will be published. 
 
13.FUTURE DEVELOPMENT 
The introduction of the adjuvant setting would change our way of looking and studying the 
disease, swithching from the main goal that was disease free survival to a longer vision of the 
disease. Already in the era of immunotherapy we have assisted to longer melanoma specific 
survival even despite quick relapse free survival or even progression after first relapse.  
The use of PD-1 inhibitors in the adjuvant setting has been a major discussion topic in last years. 
Some of the challenges of assessing these drugs in the adjuvant setting include choosing a 
comparator arm, due to the standard of care being unclear, patient selection, unexpected 
toxicity, and deciding how long to treat the patient. Another challenge is presented by the 
selection of a meaningful primary endpoint, whether that is OS or RFS.. An interesting question 
on the role of adjuvant therapies has to be raised: is it important to start a treatment in the 
adjuvant setting which means to treat a robust percentage of patients who are already potentially 
cured with surgery or, at the end, the survival obtained will be the same in case patients are 
treated only after recurrence of their disease? 
 There are some data suggested that due to the primed immune system you get more toxicity in 
the adjuvant setting than in the advanced disease setting [39]. A number of important questions 
have found response by trials mentioned above, but remain many other questions that need to be 
settled regarding the use of anti–PD-1 blockade in the adjuvant setting. For example if PD-L1 
expression in resected melanoma tumors serve as a biomarker for successful adjuvant treatment, 
and if there are other novel biomarkers that could be used in order to differentiate between 
patients who will derive the    most benefit from treatment, without exposing 
to unnecessary ineffective and toxic treatment this population. In conclusion, a major advantage 
of immunotherapy is the possibility to discontinue treatment and maintain antitumor responses. 
The immunological ‘memory’ induced by the immunotherapy agent offers the potential for long-
lasting, possibly life-long, therapeutic responses. 
 
 
For sure the identification of the patietns is a matter of debate and will be one of the first issue to 
be solved. The American Joint Committee on Cancer (AJCC) has reported in its 8th edition a  
melanoma-specific survival (MSS) for all stage sub- groups higher than those reported in the 
seventh edition. 
 
The higher survival of patients in the more contemporary cohort examined is likely a 
consequence of the widespread use of sentinel lymph node (SLN) biopsy; the requirement of 
SLN biopsy for patients with T2 through T4 primary melanoma to be included in AJCC staging; 
and, to a lesser extent, newer imaging technologies that improve the detection of clinically occult 
metastatic disease. 
Despite this, there is still a marked prognostic heterogeneity within the same stage and a 
prognostic hierarchy between the different stages seems to lack. 
Within stage III, a new subgroup (stage IIID) has been added with respect to the previous 
edition. Consequently, the prognosis of stage IIIA patients has improved, while a higher risk 
subgroup of stage III patient has been identified.so the Anyway, no one of these trials has 
focused on stage IIC patients who may deserve of adjuvant therapy as well as stage III ones (Fig. 
2). If their results would be the base for adjuvant therapy indications, there is the risk of an unfair 
limitation to the clinical practic Anyway, no one of these trials has focused on stage IIC patients 
who may deserve of adjuvant therapy as well as stage III ones (Fig. 2). If their results would be 




Combination therapies are at the moment under consideration .  
    Programmed cell death-1 (PD1) is an immune inhibitory receptor expressed by activated T 
and B cells that binds to the two known ligands PDL1 and PDL2. PDL1 is expressed by a wide 
variety of tissues, and also on human tumors, including melanoma. When PD1 binds to its 
ligands, it negatively regulates T-cell function 65. This mechanism is used by several tumors to 
escape the immune system control. According to recent studies IFN could regulate PD1/PDL1-2 
expression resulting in a controversial pro-tumor escape effect . In fact, CD8+ T cells matured in 
the presence of IFN-α showing higher levels of PD1 and a relatively poor ability to inhibit tumor 
growth efficiently66. Moreover, IFN-α has been reported to increase PDL1 cellular expression on 
hepatocytes67, and IFN-γ on tumor cells68 . These lines of evidence support the hypothesis that 
IFN-α-mediated anti-tumor activity would be significantly enhanced through PD-1 blockade. 
The combination of the anti-PD1 pembrolizumab and pegylated IFN-α2b was recently tested in a 
phase I clinical trial and was well tolerated with no dose limiting toxicities and mostly grade 1 
adverse events. Enrolled patients were affected by recurrent inoperable stage III and IV 
melanoma and previous treatments included adjuvant IFN, vemurafenib, chemotherapy, and 
radiotherapy. Six out of 12 patients were evaluated for clinical responses at week 12 with 1 
complete response, 4 stable disease, and 1 progressive disease with mixed clinical responses69. In 
stage II, we do not have studies at the moment with new adjuvant treatments, although those 
patients represent a big percentage of the total amount of potential candidates to an adjuvant 
treatment. In the latter, to decrease DFS while increasing the OS will globally  impact even more 
than in stage III on the global survival of melanoma patients. 
 
 
Not completely similarly to advanced disease we shall now face a new difficult decision to be 
taken at least in half of the patients: which therapy to adopt in the adjuvant setting for patients 
presenting BRAF mutation? In metastatic disease we shall always have the chance to propose 
both treatments and the main issue is to decide which to propose as first line, and in this advance 
disease patients population the choice is usually justified or motivated on the basis of an empiric 
feeling: offer a target therapy to patients with bulky, aggressive disease, and a immunotherapy to 
more chronic low aggressive metastatic progression of melanoma. Can we apply the same 
philosophy to the adjuvant setting? Probably not, but more than this, in the adjuvant setting we 
shall be able to offer only one treatment schedule, so the choice will be at this stage more a 
patient to patient discussion then a decision driven from clinical or biological issues: patients 
with easy accessibility to the hospital willing to receive ev. Injection every 3 weeks will be 
offered immunotherapy, while older, less geographically accessible patients with less sun 
exposure risk may prefer the oral approach of target therapy. 
 
The large spectrum of prognosis in stage III patients is opening a huge request of biomarker to 
evaluate the risk of progression and to identify whom out of all the  patients will develop a 
disease progression. Many clinical and pathologic prognostic factors have been evaluated. 
Clinically age and phenotype (like mole count) has been demonstrated to play a role in survival 
in positive SLN patients70. Pathologic features of primary like Breslow thickness, ulceration, 
mitoses and regression have been associated to prognosis as well as the number of lymph node 
excised and the number of positive ones5,6,71. Genetic biomarkers are now under evaluation. The 
urgent need of biomarker has increased after the discovery of efficacy in the adjuvant therapy in 
terms of increasing survival. To be able to detect which patients are at risk of progression and so 
to candidate only those ones to adjuvant therapy would be the next goal of melanoma research.  
Last topic under study will be the concept of neoadjuvant therapies: this approach could be 
proposed in different scenarios i.e. for stage III palpable nodal disease and for stage IV 
melanoma patients. Years ago the only possibly effective therapy was surgery. Now 2 studies 
demonstrate that surgery is no more the gold standard and new hypothesis are under 
investigation  from the medical point of view. In stage IV on the contrary, surgery could be seen 
as a confirmation of efficacy of medical treatments where both a complete response or a partial 
response have been reached, offering to patients the opportunity of interrupting their medical 





Melanoma clinical research during the last 10 years has driven the most important changes in 
treatment approaches seen in oncology since ever. From being an orphan and neglected disease it 
has moved to the most pioneering tumor  from which so many other cancer types are learning 
and developing new strategies72. Advanced disease has demonstrated an impressive treatment 
efficacy improvement passing from 5% to more then 50% survival benefit at 5 years. From these 
results a new set of trials have been developed in the adjuvant setting and the results of the first 
studies have been recently offered to the scientific community to become common practice as 
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